Following a favorable ruling from the Federal Circuit, Johnson & Johnson’s Janssen subsidiaries have initiated lawsuits against Sun Pharma in federal courts in New Jersey and Delaware. These legal actions were prompted by Sun Pharma’s intent to market generic versions of Janssen’s schizophrenia medication, Invega Sustenna. Janssen’s recent victory at the Federal Circuit reinforced its patent claims on the drug, providing momentum for the company’s legal strategy against potential generic competitors. The [initial report](https://www.law360.com/ip/articles/2364338?utm_source=rss&utm_medium=rss&utm_campaign=section) from Law360 outlines these developments and sheds light on Janssen’s legal maneuvers.
The litigation against Sun Pharma is part of a broader strategy by pharmaceutical companies to extend patent protections and delay the entry of generics, a common practice in the industry that continues to generate debate. The outcome of this case will impact the pharmaceutical landscape, potentially affecting pricing and availability of schizophrenia treatments.
This legal maneuvering follows consistent efforts by Janssen to protect its intellectual property. Their success in the Federal Circuit came after they defeated a patent challenge, demonstrating the robustness of their legal claims. The decision underscored the complexities of patent law, particularly in the context of pharmaceuticals, where patent lifecycles and generic competition are critical issues.
These developments are closely watched by stakeholders across the pharmaceutical and legal sectors. For legal professionals involved in patent litigation, Janssen’s recent actions highlight the intricate dynamics of defending proprietary pharmaceutical assets against generic manufacturers.